Bedrijfsoverzicht
China Pharma Holdings, Inc. is a specialized entity within the healthcare sector that focuses on the development, manufacturing, and marketing of pharmaceutical products specifically for the human market in the People's Republic of China. The company's product portfolio is diverse, encompassing dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions, which positions it within the drug manufacturers specializing in specialty and generic pharmaceuticals. As of the latest available data, the enterprise operates with a market capitalization of $3.24M and employs a workforce of 215 individuals. With an annual revenue of $4.14M, the company operates on a small scale relative to large-cap pharmaceutical peers, indicating a niche presence in the broader industry.
Financiële gezondheid
The company reported a revenue of $4.14M over the trailing twelve months, yet this figure is significantly offset by a net income of $-3,187,556 and an EBITDA of $-1,583,887, revealing a cost structure where expenses substantially exceed operational and overall earnings. Despite the negative net income, the entity maintains a positive free cash flow of $1.05M, which suggests a degree of financial flexibility derived from capital management or asset sales rather than core operating profitability. The gross margin stands at -3.2%, the operating margin at -97.9%, and the profit margin at -76.9%, indicating severe cost pressures that erode value at every stage of the income statement. On the balance sheet, the company holds $345,112 in cash while carrying $3.89M in debt, resulting in a debt-to-equity ratio of 17.09, which characterizes a highly leveraged financial position rather than a conservative one. The current ratio of 0.32 further highlights significant short-term liquidity constraints, as current liabilities exceed current assets. Additionally, the return on equity is -20.9% and the return on assets is -8.4%, metrics that collectively demonstrate that management's current strategies are resulting in value destruction rather than generating returns on the capital base.
Waarderingsbeoordeling
The P/E ratio (TTM) is listed as N/A and the forward P/E is also N/A, implying that traditional earnings-based valuation models are not applicable due to the company's consistent losses and lack of expected earnings recovery in the near term. The price-to-book ratio is 0.44, which indicates that the market is valuing the company at less than half of its book value, suggesting a deep discount relative to its accounting equity. Alternative valuation metrics such as the price-to-sales ratio of 0.78 and the EV/EBITDA of -18.76 provide further context, showing that the company trades below one dollar of sales per dollar of revenue and has negative enterprise value relative to earnings. The stock has a 52-week high of $2.60 and a 52-week low of $0.50, placing the current trading price well within the historical range but requiring specific market data to determine the exact percentage distance from these extremes at any given moment. The beta of 1.09 suggests that the stock's price volatility moves in tandem with the broader market, exhibiting slightly higher sensitivity to general market fluctuations than a beta of 1.0 would indicate.
Growth & Income
China Pharma Holdings, Inc. achieved a revenue growth rate of 8.1% year-over-year, whereas the earnings growth rate is N/A due to the absence of positive net income, implying that top-line expansion is currently not translating into bottom-line profitability. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm retains all available cash flow to fund operations, debt service, or potential growth initiatives rather than distributing income to shareholders. This reinvestment strategy is typical for companies in a developmental or loss-making phase where capital preservation is prioritized over shareholder distributions. The overall growth and income profile presents a dichotomy of modest top-line expansion coupled with significant operational losses and a complete lack of income distribution, reflecting the high-risk nature of the current business model.